 MediciNova Inc NASDAQ: MNOV announced that secondary analysis of the Phase 2 trial of MN-166 ibudilast in alcohol use disorder AUD was published in the journal Alcoholism: Clinical and Experimental Research. The publication describes a secondary analysis of a two-week clinical. 